Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986488 in Advanced Malignant Tumors
NCT06764771Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of bms-986488 in clear cell renal cell carcinoma (ccRCC), clear cell ovarian cancer, non-small cell lung cancer (NSCLC) and 2 more (8 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Adverse Events, Serious Adverse Events and 3 more. Started Mar 2025; status: recruiting.
02
Drugs
bms-986488
03
Conditions
clear cell renal cell carcinoma (ccRCC)clear cell ovarian cancernon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06764771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06764771.